Shares of Annexon, Inc. (NASDAQ:ANNX – Get Free Report) have received an average rating of “Buy” from the six brokerages that are presently covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $15.80.
ANNX has been the subject of several research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $16.00 target price on shares of Annexon in a research report on Tuesday, March 4th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Annexon in a research report on Tuesday, December 17th.
View Our Latest Analysis on ANNX
Institutional Investors Weigh In On Annexon
Annexon Trading Up 2.8 %
Shares of NASDAQ:ANNX opened at $2.60 on Thursday. The stock’s fifty day simple moving average is $3.49 and its two-hundred day simple moving average is $5.21. Annexon has a 1-year low of $2.30 and a 1-year high of $8.40. The stock has a market cap of $285.25 million, a PE ratio of -2.48 and a beta of 1.14.
Annexon (NASDAQ:ANNX – Get Free Report) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.05). On average, sell-side analysts forecast that Annexon will post -0.96 earnings per share for the current fiscal year.
About Annexon
Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.
See Also
- Five stocks we like better than Annexon
- What Is WallStreetBets and What Stocks Are They Targeting?
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Growth Stocks: What They Are, Examples and How to Invest
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- How to Use the MarketBeat Dividend Calculator
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Annexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annexon and related companies with MarketBeat.com's FREE daily email newsletter.